Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
tolvaptan
|
| gptkbp:approvalYear |
2009
|
| gptkbp:ATCCode |
C03XA01
|
| gptkbp:CASNumber |
150683-30-0
|
| gptkbp:chemicalFormula |
C26H25ClN2O3
|
| gptkbp:contraindication |
anuria
hypovolemic hyponatremia |
| https://www.w3.org/2000/01/rdf-schema#label |
Samsca
|
| gptkbp:indication |
gptkb:autosomal_dominant_polycystic_kidney_disease
hyponatremia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:mechanismOfAction |
vasopressin V2 receptor antagonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dry mouth
thirst polyuria hypernatremia |
| gptkbp:tradeNameOf |
tolvaptan
|
| gptkbp:bfsParent |
gptkb:Otsuka_Pharmaceutical_Co.
gptkb:Otsuka_Holdings |
| gptkbp:bfsLayer |
6
|